Mapping SARS-CoV-2 antigenic relationships and serological responses.

Autor: Wilks SH; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK., Mühlemann B; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany., Shen X; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA., Türeli S; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK., LeGresley EB; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK., Netzl A; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK., Caniza MA; Department of Global Pediatric Medicine, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA., Chacaltana-Huarcaya JN; Hospital Nacional Daniel A. Carrión, Callao, Bellavista, Peru., Corman VM; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany., Daniell X; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., Datto MB; Department of Pathology, Duke University School of Medicine, Durham, NC, USA., Dawood FS; Centers for Disease Control and Prevention, Atlanta, GA, USA., Denny TN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA., Drosten C; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany., Fouchier RAM; Erasmus Medical Center, Rotterdam, Netherlands., Garcia PJ; School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru., Halfmann PJ; Influenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA., Jassem A; BC Centre for Disease Control, Vancouver, British Columbia, Canada., Jeworowski LM; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany., Jones TC; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany., Kawaoka Y; Influenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.; Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Tokyo, Japan., Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Pathology, Cellular and Molecular Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., McDanal C; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., Pajon R; Moderna, Inc., Cambridge, MA, USA., Simon V; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Pathology, Cellular and Molecular Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Stockwell MS; Division of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, and Department of Population and Family Health, Mailman School of Public Health, New York, NY, USA., Tang H; Department of Surgery, Duke University School of Medicine, Durham, NC, USA., van Bakel H; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Veguilla V; Centers for Disease Control and Prevention, Atlanta, GA, USA., Webby R; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA., Montefiori DC; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA., Smith DJ; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
Jazyk: angličtina
Zdroj: Science (New York, N.Y.) [Science] 2023 Oct 06; Vol. 382 (6666), pp. eadj0070. Date of Electronic Publication: 2023 Oct 06.
DOI: 10.1126/science.adj0070
Abstrakt: During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multiple variants escaping preexisting immunity emerged, causing reinfections of previously exposed individuals. Here, we used antigenic cartography to analyze patterns of cross-reactivity among 21 variants and 15 groups of human sera obtained after primary infection with 10 different variants or after messenger RNA (mRNA)-1273 or mRNA-1273.351 vaccination. We found antigenic differences among pre-Omicron variants caused by substitutions at spike-protein positions 417, 452, 484, and 501. Quantifying changes in response breadth over time and with additional vaccine doses, our results show the largest increase between 4 weeks and >3 months after a second dose. We found changes in immunodominance of different spike regions, depending on the variant an individual was first exposed to, with implications for variant risk assessment and vaccine-strain selection.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje